Massey researchers co-lead global breast cancer trials
Massey researchers are part of two international leadership teams recruiting subjects for phase 3 clinical trials testing novel breast cancer therapies. The first trial, known as KATHERINE, will test the efficacy and safety of a new antibody-drug conjugate, trastuzumab emtansine (T-DM1), in comparison to the standard FDA-approved drug Herceptin as post-operative, or “adjuvant”, therapy for early stage Human Epidermal Growth Factor Receptor 2-positive (HER2+) breast cancer patients. The second trial, OlympiA, will test the efficacy of the drug olaparib as adjuvant therapy for high risk, triple negative breast cancer patients with inherited loss of the BRCA1 or BRCA2 cancer suppressor genes.
Novel model developed to predict nicotine emitted from e-cigarettes
VCU Massey Cancer Center researchers at the VCU Center for the Study of Tobacco Products (CSTP) have developed the first ever, evidence-based model that can predict with up to 90 percent accuracy the amount of nicotine emitted by an electronic cigarette (e-cigarette).
The researchers, working in collaboration with investigators at the American University of Beirut, The model predicted that higher voltage e-cigarette devices paired with high-concentration nicotine liquids could emit greater levels of the addictive substance than those of a traditional tobacco cigarette, depending on user puff duration.
Massey researchers find link between cancer gene and obesity
Recent discoveries suggest that the gene Astrocyte elevated gene-1 (AEG-1) could even be controlled with certain therapies to prevent or reverse obesity and obesity-related cancers.
Massey researcher part of global scientific task force that found linkages between mixtures of commonly encountered chemicals and the development of cancer
A global scientific task force involving VCU Massey Cancer Center researcher Masoud Manjili, Ph.D., found that combinations of chemicals encountered every day in our air, food and water can lead to the development of cancer. Assembled by an NGO called “Getting to Know Cancer,” the task force consisted of 174 total scientists from prominent institutions in 28 countries who collaborated to tackle longstanding concerns over the linkages between mixtures of commonly encountered chemicals and the development of cancer.
Massey researcher selected as national leader for large-scale NCI clinical trial
Known as the NCI-MATCH trial – National Cancer Institute Molecular Analysis for Therapy Choice Program, the study will consist of numerous small, phase 2 trials that will examine solid tumors and lymphomas that no longer respond to standard treatment and have begun to grow. Next-generation DNA sequencing will be administered on tumor biopsies from as many as 3,000 patients nationwide to determine the cell’s “broken” mechanism and, therefore, what is causing the cancer growth.